The full content of Annals is available to subscribers

Subscribe/Learn More  >
Original Research |

Hemodynamic Response to Oxygen Therapy in Chronic Obstructive Pulmonary Disease

[+] Article, Author, and Disclosure Information

Contract support: by contracts NO1-HR-6-2942, 2943, 2944, 2945, 2946, and 2947 and NO1-HR-34001 from the Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health.

Participants in the Nocturnal Oxygen Therapy Trial are as follows (asterisks indicate principal investigators):

Clinical Centers: Henry Ford Hospital, Detroit, Michigan: Paul A. Kvale, M.D.*; William A. Conway, M.D.; E.O. Coates, Jr., M.D.; George C. Bower, M.D.; Fareed U. Khaja, M.D.; Kenneth M. Adams, Ph.D.; Julia A. Lee, M.S.; Marcia Lopacz, R.N., M.S.N.; and Jennifer Reeves, R.N.

Northwestern University, Chicago, Illinois: David W. Cugell, M.D.*; Norman Solliday, M.D.; John Campbell, M.D.; William Kuczerpa, M.D.; Diane Judge, R.N.; and Carmen Zych, R.N.

University of Manitoba, Winnipeg, Manitoba: Nicholas R. Anthonisen, M.D.*; Morley M. Lertzman, M.D.; John A. Fleetham, M.D.; Janet Clarke, R.N.; and Ann McBurney, R.N.

University of California and Scripps Clinic Research Foundation, San Diego, California: Richard M. Timms, M.D.*; Patty Nordgren, R.N.; Richard Bordow, M.D.; Dale Kocienski, M.D.; and Connie Neveu, M.T.

University of Colorado, Denver, Colorado: Thomas L. Petty, M.D.*; Thomas A. Neff, M.D.; Enrique Fernandez, M.D.; Louise M. Nett, R.N., R.R.T.; Robert Maulitz, M.D.; Ruth Harada, M.D.; and Michael D. Baird, B.S.

University of Southern California, Los Angeles, California: C. Thomas Boylen, M.D.*; John Mohler, M.D.; Hugo Chiodi, M.D.; Daniel Kanada, M.D.; Elaine Layne, R.N.; Sylviane Herzog, M.D.; and Peggy Pegg, R.N.

Data Center: University of Michigan, Ann Arbor, Michigan: George W. Williams, Ph.D.; and Sandy M. Snedecor, B.S.

Neuropsychology Centers: Veterans Administration Medical Center and University of California, San Diego: Igor Grant, M.D.; and Robert Reed, M.S.; University of Colorado, Denver, Colorado: Robert H. Heaton, Ph.D.; and Susan Heaton, B.A.

Quality of Life Assessment: University of West Virginia, Morgantown, West Virginia: A. John McSweeny, Ph.D.

Pathology Center: University of Manitoba, Winnipeg, Manitoba: William M. Thurlbeck, M.D.

Advisory Board: Marvin A. Sackner, M.D. (chairman); Stephen M. Ayres, M.D.; B. William Brown, Ph.D.; Millicent Higgins, M.D., D.P.H.; Philip Kimbel, M.D.; Jeanne K. Malchon; Harold Menkes, M.D.; William F. Miller, M.D.; and Louis Vachon, M.D.

National Heart, Lung, and Blood Institute: Lynn H. Blake, Ph.D.; David DeMets, Ph.D.; Claude Lenfant, M.D.; Hannah Peavy, M.D.; and Richard Sohn, Ph.D.

▸Requests for reprints should be addressed to Richard M. Timms, M.D.; Division of Chest Medicine, Scripps Clinic and Research Foundation, 10666 North Torrey Pines Road; La Jolla, CA 44106.

THE NOCTURNAL OXYGEN THERAPY TRIAL GROUP; La Jolla, California; Detroit, Michigan; and Cleveland, Ohio

© 1985 American College of PhysiciansAmerican College of Physicians

Ann Intern Med. 1985;102(1):29-36. doi:10.7326/0003-4819-102-1-29
Text Size: A A A

At six centers, 203 patients with stabilized hypoxemic chronic obstructive pulmonary disease were evaluated hemodynamically during a continuous or 12-hour oxygen therapy program. Neither oxygen therapy program resulted in correction or near-correction of the baseline hemodynamic abnormalities. The continuous oxygen therapy group did show improvement in pulmonary vascular resistance, pulmonary artery pressure, and stroke volume index. The improvement in pulmonary vascular resistance was associated with improved cardiac function, as evidenced by an increase in baseline and exercise stroke volume index. The nocturnal oxygen therapy group showed stable hemodynamic variables. For both groups, changes in mean pulmonary artery pressure during the first 6 months were associated with subsequent survival after adjustment for association with the baseline mean pulmonary artery pressure. Continuous oxygen therapy can improve the hemodynamic abnormalities of patients with hypoxic chronic obstructive pulmonary disease. The hemodynamic response to this treatment is predictive of survival.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.